GRENSSAP

Research Group in Primary Health Services

This research group on primary care services in Catalonia is made up of a team of researchers from IDIAP Jordi Gol who have been working in various lines of research in health services for several years, and participate in important evaluation and innovation processes in primary care in Catalonia (evaluation of the objectives of the Catalan Health Service,  impact of electronic guides, role of nursing in the care of acute problems, evaluation of a new model for emergency services, validation of Adjusted® Clinical Groups, etc.).

Many of its members participated in the redIAPP network between 2003 and 2006 or in the IRYSS network (Health Outcomes and Services Research: G03/2020). In 2006 he rejoined the redIAPP network. In 2009 it was accredited as an emerging group by the Department of Innovation, Universities and Business of the Generalitat de Catalunya. The general objective of the group is the research and systematic evaluation of general and specific aspects of the development and functioning of health services and their relationship with the factors that affect health.

Group projects

• Improvement in Fundanet-GIR Integration. (MDG-23-11571). Spanish Foundation for Science and Technology (FECYT). 2023-2026. IP: Anna Moleras Serra.
• Kinetics of humoral immune response over 17 months of covid 19 pandemic in a large cohort of healthcare workers in spain: the PROHEPIC 19 Study. Official College of Physicians of Barcelona; Fundació Academia Ciencies Mediques de Catalunya I de Balears (L'Acadèmia). 2023-2024. PI: Concepció Violán Fors.
• Strategy to strengthen the PROSAARU research group in Central Catalonia. ICS - Catalan Institute of Health. 2023-2027. IP: Glòria Saüch Valmaña.
• Review on social cohesion: evidence on the association between social cohesion/social capital and health, as well as the approach and implementation of public policies in this area. American Health Organization/World Health Organization (PAHO/PAHO). 2022-2025. PI: Constanza Jacques Aviñó.
• DARWIN-EU. European Medicines Agency (EMA). 2022IP: Talita Duarte Salles. -Gender perspective and cardiovascular risk factors in diabetes. ICS - Catalan Institute of Health. 2022-2024. PI: Anna Mª Ramírez Morros.
• Sara Borrell ISCIII 2021. (CD21/00124). Carlos III Health Institute. 2021-2024. IP: Laura Medina Perucha.
• Construction and validation of a predictive score of risk of institutionalization, hospital admissions and mortality, in people over 65 years of age with multimorbidity and frailty. (FI20/00040). Carlos III Health Institute. 2020-2025. PI: Lucía Amalia Carrasco Ribelles.
• IMPACT PlatformProgram 1 Predictive Medicine IMP/00021. (IMP/00021). Consortium Center for Biomedical Research in RED (CIBER); Carlos III Health Institute. 2020-2024. PI: Josep Basora Gallisà, Bonaventura Bolíbar Ribas.
• IMPACT Platform Program 2 - Data Science. (IMP/00019). Barcelona Supercomputing Center (BSC-CNS); Carlos III Health Institute. 2020-2024. PI: María Aragón Pérez.
• Multimorbidity and Frailty Trajectories and Explainable Prediction Models for Health-related Outcomes Using Longitudinal Electronic Health Records of the Ageing Catalan Population. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). PI: Lucía Amalia Carrasco Ribelles.
• Cardiac PASS Thesis - SIDIAP Feasibility Questionnaire. IQVIA LTD. 2023-2024. IP: Maria Giner Soriano.
• Evaluation of the Childhood Obesity and Emotional Well-Being Health Plan (commissioned by the Department of Health). Generalitat Catalunya. 2023-2025. IP: Anna Berenguera Ossó.
• TADIA_MED. Polytechnic University of Catalonia (UPC). 2020-2024. PI: Concepció Violán Fors.
• Living Lab to co-create and test things with university students. LIVING LAB UNIVERSITARI URV. PI: Constanza Jacques Aviñó.
• Mobile app for nystagmographies incorporated into a diagnostic algorithm for benign paroxysmal peripheral vertigo. NYSTAVERT. Primary Care Foundation (FAP)
• CAMFIC; Migranodearena Foundation. PI: José Luis Ballvé Moreno. - COMPARTIM, App for people with mild or moderate ID. PI: Diana Puente Baliarda.
• ONALABS: ONAVITAL. PI: Concepción Violán Fors. -Practical introduction to OMOP data analysis. PI: Talita Duarte Salles.
• Emotional health, care and perimenopause: a qualitative and participatory study for the co-creation of a guide for the development of public policies in the city of Barcelona. (24S05923-001). Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol); Institut Municipal Hisenda BCN AJUNTAMENT DE BARCELONA. 2024-2027. IP: Laura Medina Perucha.
• Mental health in adolescents and young people in Barcelona from a perspective of social inequalities: a population and qualitative participatory study. (24S05920-001). Municipal Institute of Finance BCN - BARCELONA CITY COUNCIL; Carlos III Health Institute. 2024-2026. PI: Constanza Jacques Aviñó.
• DARWIN EU® - Incidence of suicidality in patients with specific chronic skin conditions. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2027. IP: Talita Duarte Salles.
• DARWIN EU® - Suicidality following exposure to doxycycline. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2025. IP: Talita Duarte Salles.
• Evaluación del Plan de Salud de Cataluña 2021 - 2025 Bienestar emocional y Obesidad Infantil, desde la perspectiva de Caso. Generalitat Catalunya. 2024-2026. IP: Anna Berenguera Ossó.
• DARWIN EU® - Comparing direct and indirect methods to estimate prevalence of chronic diseases using real-world data. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2025. IP: Talita Duarte Salles.
• Characterization of primary care teams in Catalonia and prediction of avoidable hospital admissions during the period 2018-2022. Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol). 2024-2027. PI: Concepció Violán Fors.
• Time trends in prevalence, incideTime trends in prevalence, incidence and survival of cancer in the OHDSI Network and survival of cancer. 2024-2026. IP: Talita Duarte Salles.
• Study of the use of drugs for the treatment of heart failure. Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol). 2024-2027. IP: Maria Giner Soriano.
• DARWIN EU® - Effectiveness of COVID-19 vaccines on severe COVID-19 and post-acute outcomes of SARS-CoV-2 infection. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2026. IP: Talita Duarte Salles.
• DARWIN EU® - Age-specific incidence rates of RSV-related disease in Europe. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2025. IP: Talita Duarte Salles.
• Lifetime adiposity and cancer risk and mortality: the role of comorbidities and weight loss interventions. (PI23/01186). Carlos III Health Institute. 2024-2026. IP: Talita Duarte Salles.
• Safety of Paxlovid among patients with moderate or severe hepatic or renal impairment (C4671047, VAC4EU & SIGMA study). Research Triangle Institute (RTI). 2023-2025. IP: Maria Giner Soriano.
• Evaluation of an interdisciplinary program optimized to improve the quality of life of people with fibromyalgia: quasi-experimental study (FIBROcatcentral). 2023-2026. IP: Glòria Saüch Valmaña.
• DARWIN EU® - Monitoring prescription of medicines for public health emergencies at risk of shortages. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2025. IP: Talita Duarte Salles.
• Safety of Paxlovid during pregnancy (C4671037, VAC4EU & SIGMA study). Research Triangle Institute (RTI). 2023-2026. IP: Maria Giner Soriano.
• DARWIN EU® - EHDS Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 in the context of the OMICRON variant. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2025. IP: Talita Duarte Salles.
• Construction and validation of a predictive score of risk of institutionalization, hospital admissions and mortality, in people over 65 years of age with multimorbidity and frailty - SNAC-K validation (OMOP). 2023-2026. PI: Concepció Violán Fors.
• Mapping and monitoring of the prescription of antibiotics at the level of the South Metropolitan Territorial Management. 2023-2026. IP: Gemma Rodríguez Palomar,Mònica Monteagudo Zaragoza.
• Major haemorrhages in patients treated with anticoagulants and pharmacological interactions: a case-control study with data from the clinical history of Primary Care in Catalonia. 2023-2026. IP: Maria Giner Soriano.
• Comparison of the effectiveness of drugs in the first line of preventive treatment of migraine in Primary Care: pragmatic clinical trial. Study PREMI. (ICI23/00047). Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol); Carlos III Health Institute. 2023-2026. IP: Maria Giner Soriano.
• DARWIN EU® - DUS in patients with major depressive disorder. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2025. IP: Talita Duarte Salles.
• DARWIN EU® - Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2025. IP: Talita Duarte Salles.
• DARWIN EU® - DUS of medicines with prokinetic properties in children and adults diagnosed with gastroparesis. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024. IP: Talita Duarte Salles.
• DARWIN EU® - Natural history of dermatomyositis (DM) and polymyositis (PM) in adults and paediatric populations. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024. IP: Talita Duarte Salles.
• VAC4EU Postauthorisation Effectiveness Study of BIMERVAX® Vaccine in Europe. Research Triangle Institute (RTI). 2023-2026. IP: Felipe Villalobos Martínez.
• DARWIN EU® - Use of take-home naloxone for opioid overdose treatment. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024. IP: Talita Duarte Salles. -DARWIN EU®
• Drug utilization study of prescription opioids. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2023-2024. IP: Talita Duarte Salles.
• Bienestar emocional y social en mujeres y personas en la etapa de la perimenopausia Cataluña: un estudio de fotovoz. 2023-2025. IP: Laura Medina Perucha.
• Estudi descriptiu sobre la migranya. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023-2026. IP: Maria Giner Soriano.
• Desarrollo de un modelo predictivo de falta de adherencia terapéutica en el contexto del proyecto BEAMER. 2023-2026. IP: Maria Giner Soriano.
• Development of new growth curves for children and adolescents in Catalonia. 2023-2026. IP: Talita Duarte Salles.
• DARWIN EU® - Multiple myeloma: patient characterisation, treatments and survival in the period 2012-2022. 2023-2024. IP: Talita Duarte Salles.
• Real-world coverage and effectiveness of COVID-19 vaccines in vulnerable populations living in Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023-2026. IP: Talita Duarte Salles.
• DARWIN EU® - Background rates of serious adverse events to contextualise safety signals in a clinical trial in adolescent and adult patients with severe asthma. 2023-2024. IP: Talita Duarte Salles.
• Clinical course, outcomes and risk factors of myocarditis following administration of mRNA-1273 (ELASOMERAN). Julius Clinical Research B.V. 2023-2025. IP: Felipe Villalobos Martínez.
• La salud emocional adolescente desde una perspectiva crítica: foto-elicitación en el Raval. 2023-2025. IP: Constanza Jacques Aviñó. -Atención cenrtrada en la persona y calidad de vida en mujeres con dispareunia. (PIFIISC22/28). Fundación Canaria Instituto de Investigación Sanitaria de Canarias. 2023-2026. IP: Laura Medina Perucha.
• Epidemiology and burden of imminent subsequent fractures in postmenopausal women. University of Oxford. 2023-2026. IP: Carlen Reyes Reyes.
• Self-controlled case series (SCCS) study of COVID-19 vaccines and myocarditis and pericarditis (GVDN-VAC4EU-Myocarditis). 2022-2025. IP: Felipe Villalobos Martínez.
• VITTLINK: A multi-centre international database study evaluating the association of vaccine-induced thrombosis and thrombocytopenia (VITT) with COVID-19 vaccination. 2022-2024. IP: Felipe Villalobos Martínez.
• Risk of Guillain-Barré syndrome (GBS) after COVID-19 vaccination and SARS-CoV-2 infection: A self-controlled risk interval study. 2022-2024. IP: Felipe Villalobos Martínez.
• Utilització de fàrmacs Insuficiència Cardíaca. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2024. IP: Maria Giner Soriano.
• DARWIN EU® - D2.2.5_C1-001_V1.0_IDIAP rare blood cancer. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC). 2022-2024. IP: Talita Duarte Salles.
• Multimorbidity in the National Health System: Population characterization and impact of its patterns and trajectories on the elderly (MM-SNS Project). (PI22/01398). Carlos III Health Institute. 2022-2025. PI: Concepció Violán Fors.
• DARWIN EU® - DUS of Antibiotics in the 'Watch' category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use. 2022-2024. IP: Talita Duarte Salles.
• Effects of temperature and air pollution on mental health in Barcelona and its metropolitan area considering sociodemographic and geographical inequalities. (74036228-32). Municipal Institute of Finance BCN - BARCELONA CITY COUNCIL. 2022-2024. IP: Talita Duarte Salles.
• DARWIN EU® - Drug utilisation of valproate-containing medicinal products in women of childbearing potential. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2022-2024. IP: Talita Duarte Salles.
• Lantitaps validation project. 2022-2025. IP: Diana Puente Baliarda.
• Adaptation and validation of the "Practice Environment Scale of the Nursing Work Index" to the organizational context of the Primary Health Care and prison teams of the Catalan Institute of Health. 2022-2025. IP: Edurne Zabaleta del Olmo.
• Use of drugs, complementary medicine and vaccination in women and pregnant and lactating people: a qualitative study. 2022-2025. IP: Laura Medina Perucha.
• Descriptive study of the clinical characteristics and therapeutic approach of cardiovascular risk factors at the onset of type 2 diabetes (DM2) according to sex in a primary care cohort in Catalonia. 2022-2025. IP: Anna Mª Ramírez Morros.
• Evaluation of an educational intervention of menstrual equity in secondary schools in Catalonia: mixed methodology project. Catalan Women's Institute. 2022-2024. IP: Laura Medina Perucha.
• Effects of Angiotensin-converting enzyme Inhibitors and Angiotensin receptor blockers: protocol for a Spanish cohort study using routinely collected electronic health records with validation against the ONTARGET trial. London School of Hygiene & Tropical Medicine. 2022-2025. IP: Carlen Reyes Reyes.
• Effectiveness of heterologous and booster Covid-19 vaccination in 5 European countries, using a cohort approach in children and adults with a full primary Covid-19 vaccination regimen. UMC Utrecht (University Medical Center Utrecht). 2022-2024. IP: Felipe Villalobos Martínez.
• Utilization and safety of antidementia treatments: a large longitudinal population-based study in Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2025. IP: Carlen Reyes Reyes.
• Estudi de l'impacte de la pandèmia per Sars-CoV-2 en les cobertures vacunals a Catalunya. ICS - Institut Català de la Salut. 2022-2025. IP: Edurne Zabaleta del Olmo.
• Study of the drivers of late diagnosis of alcohol related disease, alone or in combination with metabolic-dysfunction associated fatty liver disease (MAFLD), and implementation and evaluation of interventions to reduce its burden (StopALD). (73890067-40). Institut Municipal Hisenda BCN - AJUNTAMENT DE BARCELONA. 2022-2024. IP: Anna Berenguera Ossó.
• Infecció post-vacunal per SARS-CoV2: Estudi de cohort per la caracterització de la resposta immune i desenvolupament d'un model de predicció per establir criteris de revacunació a Catalunya (BreakCOVID). (SLT021/21/000038). Generalitat Catalunya. 2022-2025. IP: Concepció Violán Fors.
• Salud menstrual, salud mental y calidad de vida en España: estudio de métodos mixtos y participativo para la cocreación de una guía basada en evidencia. (PI22/01389). Instituto de Salud Carlos III. 2022-2025. IP: Anna Berenguera Ossó.
• La salud mental en adolescente y jóvenes de Cataluña desde una perspectiva de género: estudio poblacional y cualitativo participativo. (PI22/01278). Instituto de Salud Carlos III. 2022-2025. IP: Constanza Jacques Aviñó.
• Characterisation and risks of long-term COVID-19 outcomes using large real world data. Instituto de Salud Carlos III. 2022-2025. IP: Talita Duarte Salles.
• Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries. Research Triangle Institute (RTI). 2022-2025. IP: Maria Giner Soriano.
• Time trends and socioeconomic factors associated with cancer incidence for five solid tumour sites in Catalonia from 2009 to 2018. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2025. IP: Talita Duarte Salles.
• Air pollution in relation to COVID-19 morbidity and mortality: a large population-based cohort study in Catalonia, Spain (COVAIR-CAT). Fundación Privada Instituto de Salud Global Barcelona (ISGlobal). 2022-2025. IP: Talita Duarte Salles.
• Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus. University of California, Los Angeles campus (UCLA). 2022-2025. IP: Talita Duarte Salles.
• Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine. IQVIA Solutions BV. 2022-2025. IP: Talita Duarte Salles. -El poder de la imagen. Investigación Acción Participativa con jóvenes procedentes de contextos interculturales de Santiago de Chile. Facultat de Medicina de la Universidad de Chile. 2022-2024. IP: Constanza Jacques Aviñó.
• Retrospective Longitudinal Study on Edoxaban in Patients with Non-Valvular Atrial Fibrillation in Europe. Syneos Health Consulting INC. 2021-2024. IP: Maria Giner Soriano.
• El diagnóstico tardío de la endometriosis en Cataluña: un estudio participativo de metodología mixta. Associació d'Afectades d'Endometriosi de Catalunya; Merck Sharp & Dohme de España, S.A. 2021-2025. IP: Laura Medina Perucha.
• An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using European Healthcare Data through VAC4EU. Teamit Institute, S.L. 2021-2025. IP: Felipe Villalobos Martínez.
• Urban and social environment and childhood obesity - a natural moving2health experiment. Fundacio "la Caixa". 2021-2024. IP: Talita Duarte Salles.
• Research Protocol for an Observational Health Data Analysis to Assess the Long-term Outcomes of Prostate Cancer Patients Undergoing Non-Interventional Management (i.e., Watchful Waiting) and the Impact of Comorbidities and Life Expectancy - PIONEER IMI's "Big Data for Better Outcomes" program. STICHTING EUROPEAN UROLOGICAL FOUNDATION. 2021-2024. IP: Talita Duarte Salles.
• Drug utilisation studies using data mapped to the OMOP Common Data Model: a proof of concept study assessing respiratory drug use in patients with asthma or COPD. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2021-2024. IP: Talita Duarte Salles.
• Monitoring safety of Spikevax in pregnancy: an observational study using routinely collected health data in five European countries. Julius Clinical Research B.V. 2021-2024. IP: Felipe Villalobos Martínez.
• Cohort Event Monitoring of safety of COVID-19 vaccines in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy, people with prior SARS-CoV-2 infection) (WP1). European Medicines Agency (EMA). 2021-2024. IP: Felipe Villalobos Martínez.
• Real world trends in surgical procedures- an international network study. University of Oxford. 2021-2024. IP: Talita Duarte Salles.
• Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real-World Safety of Spikevax in Europe. ICS - Institut Català de la Salut; Julius Clinical Research B.V. 2021-2025. IP: Felipe Villalobos Martínez.
• Post-Authorisation Safety Study of AZD1222. A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources. Research Triangle Institute (RTI). 2021-2025. IP: Maria Giner Soriano.
• Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources (WP3). Vaccine Monitoring Collaboration for Europe (VAC4EU). 2021-2024. IP: Felipe Villalobos Martínez.
• Incidencia y factores de riesgo de la Covid-19 en pacientes respiratorios crónicos. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021-2024. IP: Mònica Monteagudo Zaragoza.
• UNravelling COVID-19 through rEal-woRld data (UNCOVER). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021IP: Talita Duarte Salles. -Comorbidity prevalence between HIV positive and HIV negative patients over 40 years of age. ICS - Institut Català de la Salut. 2021-2024. IP: Concepció Violán Fors.
• Post-Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID -19) Vaccine. (C4591021). Fondazione Penta ETS. 2021-2025. IP: Felipe Villalobos Martínez.
• Mechanisms of long-COVID and effect of COVID-19 vaccination on long-COVID. Fundacio Privada Daniel Bravo Andreu. 2021-2024. IP: Anna Berenguera Ossó.
• Population-based study of the effectiveness of combined LAMA / LABA versus LABA / ICS therapy as maintenance treatment in COPD patients in primary care. Boehringer Ingelheim España, S.A. 2021-2024. IP: Mònica Monteagudo Zaragoza.
• Examining the etiology of early-onset colorectal cancer (EOCRC) in the SIDIAP database - research protocol. International Agency for Research on Cancer (IARC). 2021-2024. IP: Talita Duarte Salles.
• Estudi de resultats en salut en diabetis mellitus tipus 2. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021-2024. IP: Maria Giner Soriano.
• Systemic glucocorticoids in the treatment of COVID-19 and risks of adverse outcomes in COVID-19 patients in the primary and secondary care setting. IQVIA Solutions BV. 2021-2024. IP: Talita Duarte Salles.
• Impact of EU label changes fluoroquinolone containing medicinal products for systemic and inhalation use: post-referral prescribing trends. IQVIA Solutions BV. 2021-2024. IP: Talita Duarte Salles.
• Professionals, health care workers healthy and infected with SARS-CoV2 long-term incidence, reinfection, serological protection and impact of vaccination: The ProHEpiC-19+ Cohort study. ICS - Institut Català de la Salut. 2021-2024. IP: Concepció Violán Fors.
• The descriptive epidemiology of Adverse Events of Special Interest for COVID-19 and other vaccines and after seasonal influenza and COVID-19 disease in SIDIAP. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021-2024. IP: Talita Duarte Salles.
• Risk of mental and behavioral disorders in relation to availability of green spaces. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021-2024. PI: Talita Duarte Salles.
• Associations between playspaces and childhood overweight and obesity in Barcelona. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021-2024. PI: Talita Duarte Salles.
• Drug Utilization Study (DUS) and Post Authorization Safety Study (PASS) on the fixed combination tramadol-dexketoprofen (DKP-TRAM). SIMG.
• Società Italiana di Medicina Generale e delle cure primarie; SIMG SERVICE CONGRESS AND EDUCATION S.R.L. 2021-2024. PI: Talita Duarte Salles.
• REVEAL Cohort. Analysis of the role of personal aptitudes as determinants of the incidence of morbidity, life styles, quality of life, use of services and mortality. (PI19/01285). Carlos III Health Institute. 2019-2024. PI: Diana Puente Baliarda, Bonaventura Bolíbar Ribas.
• Effectiveness of a training intervention to improve the approach to patients with vertigo in primary care. VERTAP clinical trial. (PI19/00736). Carlos III Health Institute. 2019-2024. PI: José Luis Ballvé Moreno.
• Menstrual health and period poverty among young people who menstruate in the Barcelona metropolitan area (Spain). La Trastienda Comunicación, S.L. 2019-2024. PI: Laura Medina Perucha.
• European Non-interventional Post Authorization Safety Study for romosozumab by the EU-ADR Alliance. 2018-2026. IP: Carlen Reyes Reyes
• Non-interventional post-authorization multi-database safety study to assess the risk of myotoxicity and hepatotoxicity in statin-exposed heart failure patients with or without concomitant use of LCZ696. Synapse Research Management Partners, s.l. 2016-2025. IP: Daniel Prieto Alhambra,Anna Berenguera Ossó.
• Post-Authorisation Safety Study of AZD1222. A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources. Research Triangle Institute - USA. IP: Maria Giner Soriano.
• DARWIN EU® - Drug utilisation of salbutamol products for inhalation and therapeutic alternative inhalation products. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
• DARWIN EU® - Antipsychotic prescribing in people with dementia in Europe: a descriptive analysis of trends and patient characteristics. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2027. IP: Talita Duarte Salles.
• Incidencia y asociación entre la exposición a las medicaciones potencialmente inapropiadas de la herramienta STOPPFall y el riesgo de eventos adversos: estudio de cohortes de base poblacional. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP: Carlen Reyes Reyes.
• A Drug Utilization Study to Evaluate the Effectiveness of Risk Minimization Measures (RMMs) for Abrocitinib in the EU Using Electronic Healthcare Data. 2024-2026. IP: Maria Giner Soriano.
• DARWIN EU® - Characterising STOPP criteria medication use in people with recurrent falls. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
• DARWIN EU® - Antipsychotic prescribing in Europe: a descriptive analysis of trends and patient characteristics. European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
• DARWIN EU® - Background incidence rates of selected vaccine adverse events of special interest (AESIs) in Europe. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
• Antiseizure meDication Exposure and Pregnancy and neonaTal outcomes research (ADEPT). Use of antiepileptics, and feasibility of studies on the association between maternal and paternal exposure to antiepileptics and adverse pregnancy, neonatal and child outcomes. (EMA/453898/2023). European Medicines Agency (EMA). 2024-2027. IP: Maria Giner Soriano.
• DARWIN EU® - Azathioprine - user characteristics. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
• Post-Authorisation Safety Study of Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5 in Europe. (C4591052). 2024-2027. IP: Felipe Villalobos Martínez.
• A framework for the post-authorisation safety monitoring and evaluation of vaccines in the EU: Study protocol for the occurrence of flares of Graves´ disease, Hashimoto´s thyroiditis, polyarteritis nodosa, autoimmune hepatitis, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, erythema nodosum, systemic lupus erythematosus, and ulcerative colitis using electronic healthcare data sources. European Medicines Agency (EMA). 2024-2027. IP: Felipe Villalobos Martínez.
• DARWIN EU® - Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications (P3 C1-004). ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
• DARWIN EU® - Drug Utilisation Studies on GLP-1 Agonists. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2024. IP: Talita Duarte Salles. -Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in Europe. Abbvie INC. 2024-2027. IP: Talita Duarte Salles.
• DARWIN EU® - Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
• Study protocol for the Teratogenic Drugs Prioritisation (TDP) project combining pre-clinical data with clinical data from ConcePTION data sources (task 7.9). 2024-2026. IP: Maria Giner Soriano
• A framework for the post-authorisation safety monitoring and evaluation of vaccines in the EU. Universiteit Utrecht. 2024-2027. IP: Felipe Villalobos Martínez.
• Asociación entre los niveles de vitamina D en sangre, los suplementos con vitamina D y las fracturas osteoporóticas en la población catalana: estudio de base poblacional. 2024-2027. IP: Carlen Reyes Reyes.
• Incidence, prevalence, and characterisation of medicines with suggested drug shortages in Europe. 2024-2026. IP: Talita Duarte Salles. - Characterization of incidental and chronic use of macrolides in patients with asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap syndrome (ACOS); a pharmacoepidemiologic drug utilization study with data mapped to the Observational Medical Outcomes Partnership
• Common Data Model (OMOP-CDM). ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC). 2024-2027. IP: Talita Duarte Salles
• DARWIN EU® - Frailty and polypharmacy among adults aged 18 and above with cancer at the time of diagnosis. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.
• Incidence and prevalence of psoriasis and psoriatic arthritis and the external validation of a prediction model for the development of psoriatic arthritis at 10 years in people diagnosed with psoriasis: a cohort study. Barcelona Supercomputing Center (BSC-CNS). 2023-2026. IP: IP no primaria -Talita Duarte Salles.
• Post-Authorisation Active Surveillance Study of Myocarditis and Pericarditis Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID 19) Vaccine. (C4591038). Fondazione Penta ETS. 2022-2025. PI: Felipe Villalobos Martínez.
• Non-interventional post-authorization safety study (EPAS) for active safety surveillance of recipients of the Pfizer-BioNTech mRNA COVID-19 vaccine in the EU. Pfizer, S.A. 2021-2024. PI: Felipe Villalobos Martínez.

Group Publications

• Sahr JN, Bennett M, Medina Perucha L, Jacques Aviño C. Emotional health in adolescents from a critical perspective: Photo-elicitation in a cross-cultural neighborhood. SSM-Qual. Res. Health. 2025; 7-Rubio R, Yavlinsky A, Escalera Zamudio M, Molinos Albert LM, Martín Pérez C, Pradenas E et al. Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later. J Infect. 2025; 90(2):106402-106402. PMID:39746406.
• Schultze A, Martin I, Messina D, Bots S, Belitser S, Carreras Martínez JJ et al. Corrigendum to "A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases" [Vaccine 42 (12) (2024) 3039-3048]. Vaccine. 2025;44126438-126438. PMID:39396886.
• Nguyen Thi Khanh H, Rigau Sabadell M, Khomenko S, Pereira Barboza E, Cirach M, Duarte Salles T et al. Ambient air pollution, urban green space and childhood overweight and obesity: A health impact assessment for Barcelona, Spain. Environ Res. 2025; 264(Pt 1):120306-120306. PMID:39510226.
• Angelats RC, Gonçalves AQ, Abellana R, Carrasco Querol N, Corts AP, Serra GG et al. Effectiveness of a Multicomponent Program for Fibromyalgia Patients in a Primary Care Setting (FIBROCARE Program): A Pragmatic Randomized Controlled Trial. J Clin Med. 2025; 14(1):PMID:39797245.
• Carrasco Querol N, Cabricano Canga L, Hernández NB, Martín Borràs C, Goncalves AQ, Vila Marti A et al. Effectiveness of the SYNCHRONIZE plus Brief Intervention in Improving Mediterranean Diet Adherence, Nutritional Quality and Intake Pattern in Persons with Fibromyalgia and Chronic Fatigue Syndrome. Nutrients. 2025; 17(1):PMID:39796445.
• Paz JP, Garcia Egea A, Jacques Avino C, Cornejo AMB, Medina Perucha L. An intersectional approach on menstrual inequity as lived by women in circumstances of socioeconomic vulnerability in an urban and rural setting in Spain: a qualitative study. Sex Reprod Health Matters. 2024; 32(1):2422155-2422155. PMID:39450492.
• Romeu CC, López GM, Espelta EG, Reverté NB, Gonçalves AQ, Jacques Aviñó C et al. Designing a multicomponent intervention to support caregivers of persons with dementia in primary care in Spain: a qualitative study of family and professional carers. BMJ Open. 2024; 14(12):PMID:39719280.
• Lozano Sánchez A, Aragonès E, López Jiménez T, Bennett M, Evangelidou S, Francisco E et al. Temporal trends and social inequities in adolescent and young adult mental health disorders in Catalonia, Spain: a 2008-2022 primary care cohort study. Child Adolesc. Psychiatry Ment. Health. 2024; 18(1):159-159. PMID:39695666.
• Pistillo A, Warkentin S, Abellana A, de Bonte J, Ranger T, Pérez Crespo L et al. Residential relocation and changes in patterns of environmental exposures by health determinants among children and adolescents in Catalonia, Spain. Environ Res. 2024; 263(Pt 2):120152-120152. PMID:39419256.
• Aznar Lou I, Zabaleta Olmo E, Casajuana Closas M, Sánchez Viñas A, Parody Rúa E, Bolíbar B et al. Correction: Cost-effectiveness analysis of a multiple health behaviour change intervention in people aged between 45 and 75 years: a cluster randomized controlled trial in primary care (EIRA study). Int J Behav Nutr Phys Act. 2024; 21(1):138-138. PMID:39654047.
• Martín Borràs C, González Serra G, Carrasco Querol N, Sansano Nadal O, Bueno Hernández N, Bestraten Del Pino P et al. Effectiveness of a brief multicomponent intervention to improve physical activity level and functional capacity in fibromyalgia and chronic fatigue syndrome (Synchronize+). Front Physiol. 2024;151441076-1441076. PMID:39717828.
• Du M, Dernie F, Català M, Delmestri A, Man WY, Brash JT et al. Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries. Eur J Intern Med. 2024;130106-117. PMID:39134452.
• Torán Monserrat P, Lamonja Vicente N, Costa Garrido A, Carrasco Ribelles LA, Quirant B, Boigues M et al. SARS-CoV-2 Infection Risk by Vaccine Doses and Prior Infections Over 24 Months: ProHEpiC-19 Longitudinal Study. JMIR Public Health Surveill. 2024; 10PMID:39648969.
• López Sánchez I, Perramon Malavez A, Soriano Arandes A, Prats C, Duarte Salles T, Raventós B et al. Socioeconomic inequalities in COVID-19 infection and vaccine uptake among children and adolescents in Catalonia, Spain: a population-based cohort study. Front Pediatr. 2024;121466884-1466884. PMID:39633820.
• Durán CE, Riefolo F, Gini R, Barbieri E, Messina D, Garcia P et al. Incidence of severe and non-severe SARS-CoV-2 infections in children and adolescents: a population-based cohort study using six healthcare databases from Italy, Spain, and Norway. Eur J Pediatr. 2024; 184(1):6-6. PMID:39535547.
• Cruz A, Cuxart Graell A, Goncalves AQ, Vazquez Villegas J, Vallejo Godoy S, Salas Coronas J et al. Delivering an innovative multi-infection and female genital mutilation screening to high-risk migrant populations (ISMiHealth): study protocol of a cluster randomised controlled trial with embedded process evaluation. BMJ Open. 2024; 14(11):PMID:39496367.
• Xie JQ, López Güell K, Dedman D, Duarte Salles T, Kolde R, López Blasco R et al. Incidence of post-acute COVID-19 symptoms across healthcare settings in seven countries: an international retrospective cohort study using routinely-collected data. EClinicalMedicine. 2024;77102903-102903. PMID:39552716.
• Segundo E, Far M, Rodríguez Casado CI, Elorza JM, Carrere Molina J, Mallol Parera R et al. A mother-child data linkage approach using data from the information system for the development of research in primary care (SIDIAP) in Catalonia. J Biomed Inform. 2024;159104747-104747. PMID:39510366.
• Dernie F, Corby G, Robinson A, Bezer J, Mercade Besora N, Griffier R et al. Standardised and Reproducible Phenotyping Using Distributed Analytics and Tools in the Data Analysis and Real World Interrogation Network (DARWIN EU). Pharmacoepidemiol Drug Saf. 2024; 33(11):PMID:39532529.
• Pujol Puyane T, Medina Perucha L, Lopez Jimenez T, Berenguera A. A qualitative exploration of Gestalt therapy and systemic pedagogy paediatric primary healthcare consultations in Agramunt (Spain). Prim Health Care Res Dev. 2024; 25PMID:39419823.
• González Rábago Y, La Parra Casado D, Jacques Aviñó C, (por el Grupo de Trabajo de Determinantes Sociales de la Salud de la Sociedad E , Bee Nchama M, Manzano Lorenzo J. Raza, salud y sistema sanitario: la necesidad de abordar el racismo institucional en España. Gac Sanit. 2024;38102425-102425. PMID:39368170.
• Lopez Romeo S, Subira Alvarez S, Miranda Mendizabal A, Piqueras Marques J, Leal Pujol R, Recoder S et al. Having any mental health condition before the COVID-19 pandemic as a risk factor of COVID-19 contagion during the first year of pandemic: A Spanish adult cohort. Stress Health. 2024; 40(5):PMID:39019647.
• Corby G, Barclay NL, Tan EH, Burn E, Delmestri A, Duarte Salles T et al. Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study. Transl Lung Cancer Res. 2024; 13(9):2187-2201. PMID:39430337.
• Luxi N, Ciccimarra F, Bellitto C, Raethke M, van Hunsel F, Lieber T et al. Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study. Vaccines (Basel). 2024; 12(9):PMID:39340089.
• Ramírez Morros A, Berenguera A, Millaruelo L, Buil Cosiales P, Gomez Garcia C, Cos X et al. Impact of Gender on Patient Experiences of Self-Management in Type 2 Diabetes: A Qualitative Study. Patient Prefer. Adherence. 2024;181885-1896. PMID:39290823.
• Dacosta Aguayo R, Torán Monserrat P, Carmona Cervelló M, León Gómez BB, Mataró M, Puig J et al. Multimodal neuroimaging in Long-COVID and its correlates with cognition 1.8 years after SARS-CoV-2 infection: a cross-sectional study of the Aliança ProHEpiC-19 Cognitiu. Front. Neurol. 2024;151426881-1426881. PMID:39346769.
• Tan EH, Burn E, Barclay NL, Delmestri A, Man WY, Golozar A et al. Incidence, Prevalence, and Survival of Prostate Cancer in the UK. JAMA Netw Open. 2024; 7(9):PMID:39298169.
• Khera R, Aminorroaya A, Dhingra LS, Thangaraj PM, Pedroso Camargos A, Bu F et al. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM. J. Am. Coll. Cardiol. 2024; 84(10):904-917. PMID:39197980.
• Zamora Sánchez JJ, Zabaleta Olmo E, Pérez Tortajada G, Amblàs Novellas J. Validez convergente y discriminativa del índice Frágil-VIG con el test de Pfeiffer en personas atendidas en atención domiciliaria. Rev Esp Geriatr Gerontol. 2024; 59(5):101499-101499. PMID:38754273.
• Segundo E, Carrere Molina J, Aragón M, Mallol Parera R. Advancing geospatial preconception health research in primary care through medical informatics and artificial intelligence. Health Place. 2024;89103337-103337. PMID:39151214.
• Cruz A, Sequeira Aymar E, Gonçalves AQ, Camps Vila L, Monclús González MM, Revuelta Muñoz EM et al. Epidemiology of infectious diseases in migrant populations from endemic or high-endemic countries: A multicentric primary care-based study in Spain. Trop Med Int Health. 2024; 29(9):820-832. PMID:39031944.
• Tonne C, Ranzani O, Alari A, Ballester J, Basagaña X, Chaccour C et al. Air Pollution in Relation to COVID-19 Morbidity and Mortality: A Large Population-Based Cohort Study in Catalonia, Spain (COVAIR-CAT). Res Rep Health Eff Inst. 2024; 2024(220):1-48. PMID:39468856.
• Cabedo Ferreiro RM, Liutsko L, Cos Busquets J, García Sierra R, Colldeforns Vidal M, Reyes Lacalle A et al. Environmental impact of infant feeding type, accessories used and maternal dietary habits: The GREEN MOTHER-I project, a cross-sectional study protocol. Nutr J. 2024; 23(1):97-97. PMID:39164727.
• Esteban Cledera L, Bissacco CA, Pallejá Millán M, Villalobos M, Villalobos F. Association between COVID-19 Vaccines and Menstrual Disorders: Retrospective Cohort Study of Women Aged 12-55 Years Old in Catalonia, Spain. Int J Environ Res Public Health. 2024; 21(8):PMID:39200699.
• Barclay NL, Burn E, Delmestri A, Duarte Salles T, Golozar A, Man WY et al. Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021. Sci Rep. 2024; 14(1):19069-19069. PMID:39153995.
• Bellas L, Camacho Arteaga L, Giner Soriano M, Prats Uribe A, Aguilera C, Urgell CV et al. Women's health in focus: Real-world data on valproate prescriptions during pregnancy - a cohort study in Catalonia (Spain). BMJ Open. 2024; 14(8):1-9. PMID:39134441.
• Vlacho B, Molló Iniesta À, Gratacòs M, Mata Cases M, Rubinat E, Berenguera A et al. Effectiveness of a multicomponent healthcare intervention on blood pressure and lipids among subjects with poorly controlled type 2 diabetes: Findings from the INTEGRA study. Prim Care Diabetes. 2024; 18(4):402-408. PMID:38782704.
• López Jiménez T, Plana Ripoll O, Duarte Salles T, Recalde M, Bennett M, Xavier Cos F et al. Exploring the association between metabolic syndrome, its components and subsequent cancer incidence: A cohort study in Catalonia. Cancer Med. 2024; 13(16):PMID:39149842.
• Vargas EP, Carrasco Ribelles LA, Marin Morales J, Molina CA, Raya MA. Feasibility of virtual reality and machine learning to assess personality traits in an organizational environment. Front. Psychol. 2024;151342018-1342018. PMID:39114589.
• Evangelidou S, Cuxart Graell A, Zucchelli E, Gonçalves AQ, Cruz A, Sequeira E et al. Female genital mutilation among migrants in Spain: healthcare system responses and challenges. J Travel Med. 2024; 31(6):PMID:38896034.
• Carmona Cervelló M, León Gómez BB, Dacosta Aguayo R, Lamonja Vicente N, Montero Alía P, Molist G et al. Long COVID: cognitive, balance, and retina manifestations. Front Med (Lausanne). 2024;111399145-1399145. PMID:39036098.
• Blanco EC, Llorca MRD, Martín CA, Carrasco Querol N, Goncalves AQ, Rojas ZH et al. A Predictive Model of the Start of Annual Influenza Epidemics. Microorganisms. 2024; 12(7):PMID:39065025.
• García Egea A, López Jiménez T, Jacques Aviñó C, Beltrán A, Sánchez AP, Martínez Bueno C et al. Menstrual experiences and acceptability of a menstrual equity intervention among adolescents in Catalonia (Spain). Gac Sanit. 2024;38102415-102415. PMID:39047371.
• Herrero Alonso C, López Lifante VM, Costa Garrido A, Pera G, Alzamora M, Forés R et al. Adherence to Supervised and Unsupervised Exercise Programmes in Ageing Population with Intermittent Claudication: A Randomized Controlled Trial. J Clin Med. 2024; 13(13):PMID:38999256.
• Garrigues Ramón M, Arca Arias A, Carrasco Ribelles LA, Barrios C. Haemodynamic effect of a leg compression bandage on the distal posterior tibial artery using 4D flow magnetic resonance imaging: A quantitative study. Int Wound J. 2024; 21(7):PMID:38937919.
• Lazar Neto F, Mercadé Besora N, Raventós B, Pérez Crespo L, Castro Junior G, Ranzani OT et al. Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain. Nat Commun. 2024; 15(1):5088-5088. PMID:38898035.
• Gomez Lumbreras A, Vilaplana Carnerero C, Vázquez ML, Vedia C, Morros R, Giner Soriano M. Treatment of hypertension during pregnancy: a cohort of pregnancy episodes from the SIDIAP database, Catalonia, Spain. Front Pharmacol. 2024;151346357-1346357. PMID:38953107.
• Young Silva Y, Berenguera A, Juvinyà Canal D, Martí Lluch R, Arroyo Uriarte P, Tamayo Morales O et al. Exploring personal aptitudes and personality traits that, together with social determinants, shape health behaviors and conduct: a thematic analysis based on the Capability, Opportunity, Motivation and Behavior (COM-B) change system. Front. Public Health. 2024;121387528-1387528. PMID:38898892.
• Arias GR, Corcoll JS, Arnaus MC, Vidal Alaball J, Ramírez Morros A, Solé GA. Improving quality of life in older adults with the decline syndrome: The role of occupational therapy in primary care. Aten Primaria. 2024; 56(6):102879-102879. PMID:38359516.
• Aguilar R, Jiménez A, Santano R, Vidal M, Maiga Ascofare O, Strauss R et al. Malaria and other infections induce polyreactive antibodies that impact SARS-CoV-2 seropositivity estimations in endemic settings. J Med Virol. 2024; 96(6):PMID:38874194.
• Robles C, Monfil L, Ibáñez R, Roura E, Font R, Peremiquel Trillas P et al. Impact of the COVID-19 pandemic on cervical cancer screening participation, abnormal cytology prevalence and screening interval in Catalonia. Front Oncol. 2024;141338859-1338859. PMID:38873256.
• Millat Martinez P, Gharbharan A, Alemany A, Rokx C, Geurtsvankessel C, Papageorgiou G et al. Author Correction: Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nat Commun. 2024;15(1):4352-4352. PMID:38778041.
• Montesó Curto P, Toussaint L, Kueny A, Ruschak I, Lunn S, Rosselló L et al. Emotional experiences and gender roles of men with fibromyalgia syndrome: a cross-cultural qualitative study. Front Med (Lausanne). 2024;111286729-1286729. PMID:38831991.
• Dacosta Aguayo R, Puig J, Lamonja Vicente N, Carmona Cervelló M, León Gómez BB, Monté Rubio G et al. Reduced Cortical Thickness Correlates of Cognitive Dysfunction in Post-COVID-19 Condition: Insights from a Long-Term Follow-up. AJNR Am J Neuroradiol. 2024;45(5):647-654. PMID:38575319.
• Mercadé Besora N, Guo Y, Du M, Li X, Ramírez Anguita JM, Moreno A et al. Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID-19 Pandemic. Arthritis Care Res (Hoboken). 2024;76(8):1173-1178. PMID:38523562.
• Mercadé Besora N, Li X, Kolde R, Trinh NT, Sanchez Santos MT, Man WY et al. The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. Heart. 2024;110(9):635-643. PMID:38471729.
• Reyes C, Newby D, Raventós B, Verhamme K, Mosseveld M, Prieto Alhambra D et al. Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study. Age Ageing. 2024;53(5):PMID:38783756.
• Raya Tena A, F, Martín Royo J, Casajuana Closas M, Jiménez Herrera MF, Psicodep GRP. Cost-effectiveness and cost-utility study of a psychoeducational group intervention for people with depression and physical comorbidity in primary care. Enferm. Clin. 2024;34(2):108-119. PMID:38508236.
• Martínez Marcos M, Reñé A, Zabaleta Olmo E, Guiriguet C, Gómez Durán EL, Cabezas Peña C. Measles, mumps, and rubella vaccination coverage: an ecological study of primary health care and socio-economic factors in Catalonia, Spain. J. Public Health Policy. 2024;45(2):299-318. PMID:38664542.
• Gómez I, Rodero Cosano ML, Bellón JÁ, Zabaleta Olmo E, Maderuelo Fernandez JA, Moreno Peral P et al. Examining the influence of mental health and structural determinants of health on the stage of motivational readiness for health behaviour changes: A path analysis study. J. Health Psychol. 2024;PMID:38605575.
• Pumar Méndez MJ, Lopez Dicastillo O, Hernantes N, Antón Solanas I, Zabaleta Olmo E, Rodríguez Roca B et al. Mapping health promotion practices across key sectors and its intersectoral approach at the local level: Study protocol. J Adv Nurs. 2024;80(9):3866-3874. PMID:38523570.
• Cole HVS, Vásquez Vera H, Triguero Mas M, Sánchez AF, Oliveras L, Carrere J et al. Causes, consequences and health impacts of gentrification in the Global North: a conceptual framework. J. Hous. Built Environ. 2024;39(2):1081-1102.
• Perez Porcuna TM, Noguera Julian A, Riera Bosch MT, Macià Rieradevall E, Santos Santiago J, Pujol M et al. Tuberculosis among children visiting friends & relatives. J Travel Med. 2024;31(6):PMID:38438137.
• Català M, Mercadé Besora N, Kolde R, Trinh NTH, Roel E, Burn E et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. 2024;12(3):225-236. PMID:38219763.
• Ranzani O, Alari A, Olmos S, Milà C, Rico A, Basagaña X et al. Who is more vulnerable to effects of long-term exposure to air pollution on COVID-19 hospitalisation?. Environ Int. 2024;185108530-108530. PMID:38422877.
• Medina Perucha L, Jacques Aviñó C, Holst AS, Valls Llobet C, Pinzón Sanabria D, García Egea A et al. Systemic Powers, Institutionalized Thinking and Situated Knowledge: A Qualitative Exploration on the Meanings of 'Menstruation' and 'Menstrual Health' in Spain. Sex Roles. 2024;
• Alari A, Ranzani O, Olmos S, Milà C, Rico A, Ballester J et al. Short-term exposure to air pollution and hospital admission after COVID-19 in Catalonia: the COVAIR-CAT study. Int J Epidemiol. 2024;53(2):PMID:38514998.
• Spiteri G, D'Agostini M, Abedini M, Ditano G, Collatuzzo G, Boffetta P et al. Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project. Infection. 2024;52(4):1347-1356. PMID:38326526.
• Medina Perucha L, López Jiménez T, Pujolar Díaz G, Martínez Bueno C, Munrós Feliu J, Valls Llobet C et al. Menstrual characteristics and associations with sociodemographic factors and self-rated health in Spain: a cross-sectional study. BMC Womens Health. 2024;24(1):88-88. PMID:38310222.
• Medina Perucha L, Jacques Aviñó C. Menstrual health, equity and justice: collective knowledge and menstrual policymaking in Spain. Gac Sanit. 2024;38(S1):102356-102356. PMID:38350394.
• Markus AF, Rijnbeek PR, Kors JA, Burn E, Duarte Salles T, Haug M et al. Real-world treatment trajectories of adults with newly diagnosed asthma or COPD. BMJ Open Respir Res. 2024;11(1):PMID:38413124.
• Torrell G, Puente D, Jacques Aviñó C, Carrasco Ribelles LA, Violán C, Lopez Jiménez T et al. Characterisation, symptom pattern and symptom clusters from a retrospective cohort of Long COVID patients in primary care in Catalonia. BMC Infect Dis. 2024;24(1):82-82. PMID:38225587.
• Garcia Egea A, Holst AS, Jacques Avino C, Martinez Bueno C, Berenguera A, Vicente Hernandez MM et al. Perspectives on menstrual policymaking and community-based actions in Catalonia (Spain): a qualitative study. Reprod Health. 2024;21(1):1-1. PMID:38178256.
• Carrasco Querol N, Cabricano Canga L, Hernández NB, Goncalves AQ, Angelats RC, Ariza MP et al. Nutrition and Chronobiology as Key Components of Multidisciplinary Therapeutic Interventions for Fibromyalgia and Associated Chronic Fatigue Syndrome: A Narrative and Critical Review. Nutrients. 2024;16(2):PMID:38257075.
• Gomez Lumbreras A, Vazquez ML, Vilaplana Carnerero C, Prat Vallverdu O, Vedia C, Morros R et al. Drug Exposure During Pregnancy: A Case-Control Study from a Primary Care Database. Womens Health Rep (New Rochelle). 2024;5(1):13-21. PMID:38249939.
• Lo Re VI, Cocoros NM, Hubbard RA, Dutcher SK, Newcomb CW, Connolly JG et al. Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States. Clin Epidemiol. 2024;1671-89. PMID:38357585.
• Fabiano G, Chen XH, Rathod Mistry T, Delmestri A, Njuki LN, Moayyeri A et al. Feasibility of a Federated Network Analysis Using Real-World Data Mapped to OMOP Common Data Model to Estimate Healthcare Resource Utilisation and Costs of Imminent Subsequent Fracture. Pharmacoepidemiol Drug Saf. 2024;33391-391.
• Verhamme KMC, Ridder M, Arinze JT, Inberg G, Delmestri A, Burn E et al. DARWIN EU^®-Background Rates of Outcomes of Interest in Patients with Severe Asthma. Pharmacoepidemiol Drug Saf. 2024;33685-685.
• Bellas L, Camacho L, Giner Soriano M, Aguilera C, Prats Uribe A, Agusti A. Maternal Mental Health in Focus: Real-World Data on Antidepressant Use. A Cohort Study in Catalonia. Pharmacoepidemiol Drug Saf. 2024;33663-664.
• Vojinovic D, Arinze JT, Delmestri A, Brash J, Seager S, Verdy G et al. DARWIN EU®-Drug Utilisation Study of Medicines with Prokinetic Properties in Children and Adults Diagnosed with Gastroparesis. Pharmacoepidemiol Drug Saf. 2024;3391-92.
• Raventós B, Chen XH, Stanford T, Prieto Alhambra D, Porce LM, Reyes C et al. Prescription Sequence Symmetry Analysis to Identify Prescription Cascades for Dementia Drug Treatments in the United Kingdom. Pharmacoepidemiol Drug Saf. 2024;33399-400.
• Ahmadizar F, Fortuny J, Royo AC, Plana E, Weinrib R, Esteban RG et al. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data Sources: Methods and Results of the Second Study Feasibility Assessment. Pharmacoepidemiol Drug Saf. 2024;33506-507.
• Roberto G, Messina D, Durán CE, Riera Arnau J, Garcia P, Martín Pérez M et al. Assessing the Impact of Data Diversity on Background Incidence Rates of Adverse Events of Special Interest: The Component Strategy from the COVID-19 Vaccine Monitoring Project. Pharmacoepidemiol Drug Saf. 2024;33111-111.
• Schultze A, Martin I, Messina D, Bots SH, Belitser SV, Carreras JJ et al. A Comparison of Self-Controlled Study Designs in an Analysis of COVID-19 Vaccines and Myocarditis Using Five European Databases. Pharmacoepidemiol Drug Saf. 2024;3334-34.
• Maisonneuve E, Ciccimarra F, Luxi N, Bellitto C, Raethke M, van Hunsel F et al. Cohort Event Monitoring of COVID-19 Vaccine Safety Using Patient-Reported Outcomes in Lactating Women. Pharmacoepidemiol Drug Saf. 2024;33187-187.
• Weibel D, de Luise C, Royo AC, Ryan O, Vaz T, Aguado J et al. Interim Results from the VAC4EU Post-Authorization Safety Study (PASS) Among Recipients of the Pfizer-BioNTech COVID-19 (Comirnaty^®) Vaccine in Europe. Pharmacoepidemiol Drug Saf. 2024;33499-499.
• Maisonneuve E, Ciccimarra F, Luxi N, Bellitto C, Raethke M, Van Hunsel F et al. Cohort Event Monitoring of COVID-19 Vaccine Safety Using Patient-Reported Outcomes in Pregnant Women. Pharmacoepidemiol Drug Saf. 2024;33451-452.
• Girardi A, Limoncella G, Hyeraci G, Roberto G, Bartolini CC, Paoletti O et al. Impact of Data Source Diversity on the Distribution of Key Variables in Pregnancy Cohorts Based on the ConcePTION Pregnancy Algorithm Leveraging a Random Forest Imputation Model. Pharmacoepidemiol Drug Saf. 2024;3379-80.
• Monfà R, García Sangenís A, Fernández García S, Bonilla R, Morros R, Giner Soriano M. Drug utilization study in a cohort of migraine patients from SIDIAP database, Catalonia, Spain. Basic Clin. Pharmacol. Toxicol. 2024;13556-56.
• Monfá R, Giner Soriano M, Fernández García S, Vallano A, Vives R, Morros R. Comprehensive analysis of heart failure: Characteristics, treatment and outcomes in a reduced ejection fraction patient cohort from SIDIAP database, Catalonia, Spain. Basic Clin. Pharmacol. Toxicol. 2024;13554-55.
• Munne Barellas B, García Egea A, Morros Pedrós R, Vedia Urgell C, Giner Soriano M, Medina Perucha L. Experiences prescribing medicines, alternative treatments and vaccines among health professionals in Catalonia (Spain): A qualitative study. Basic Clin. Pharmacol. Toxicol. 2024;13557-57.
• Garcia SF, Moreno AM, Soriano MG, Llor C, Campos AR, Ouchi D et al. Urinary tract infections in women: Trends in antibiotic treatment over 10 years in Catalonia, Spain. Basic Clin. Pharmacol. Toxicol. 2024;13555-55.
• Mata Ley S, Pérez IS, Fernandez L, Giner Soriano M, Camacho Arteaga L. Use of nonsteroidal anti-inflammatory drugs in pregnant women: A descriptive study in Catalonia during the period 2011-2020. Basic Clin. Pharmacol. Toxicol. 2024;13552-53.
• Serra AM, Lumbreras AG, del Olmo EZ, Pedros RM, Urgell CV. Description of the publications of research studies promoted by primary care in Catalonia. Basic Clin. Pharmacol. Toxicol. 2024;13563-63.
• De Ridder M, Arinze J, Inberg G, Delmestri A, Burn E, Mayer MA et al. DARWIN EU®- Background rates of clinical outcomes of interest in patients with severe asthma. Eur. Resp. J. 2024;64
• Arinze JT, Mayer M, Verdy G, Van Kessel M, Ramírez Anguita JM, Leis A et al. RSV-associated clinical outcomes: A decade of insight from 52 million people across Europe. Eur. Resp. J. 2024;64
• Rosa LB, Pérez Caballero R, Kilpelainen A, Blanch Lombarte O, Romero L, Peña R et al. Identification of functional peptide-specific Nsp3, NC and M SARS-CoV-2 T-cell responses in hybrid immunity. Eur. J. Immunol. 2024;541458-1458.
• Chen X, Rathod Mistry T, Fabiano G, Moayyeri A, Warden J, Reyes C et al. SUBSEQUENT FRACTURES IN POSTMENOPAUSAL WOMEN WITH FRAGILITY FRACTURES: INCIDENCE AND PATIENT CHARACTERISTICS FROM SIX EUROPEAN COUNTRIES. Aging Clin. Exp. Res. 2024;36605-605.
• Voller B, Mounier N, Tata E, Roso Llorach A, Gallego Moll C, Mancini M et al. An atlas of genetic contributions to multimorbidity. Eur. J. Hum. Genet. 2024;32787-788.
• Blay N, Carrasco Ribelles LA, Violán C, de Cid R. Disease prevalence, health-related and sociodemographic factors in the GCAT cohort. A comparison with general population of Catalonia. Eur. J. Hum. Genet. 2024;32712-713.

Theses

• Association between previous exposure to biological therapies and the incidence of serious infections in patients with rheumatoid arthritis and psoriasis. [Doctoral Thesis]. Autonomus University of Barcelona.
• Descriptive study on the use of anticoagulants in patients with chronic kidney disease: analysis based on the SIDIAP database. [Master's Thesis]. Barcelona. University of Barcelona. 2024.